NO331082B1 - Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft - Google Patents

Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft

Info

Publication number: NO331082B1
Authority: NO; Norway
Prior art keywords: formulation; reconstituted solution; kahalalide; medicament; cancer
Prior art date: 2000-10-31

Application number

NO20031860A

Other languages

English (en)

Norwegian (no)

Other versions

NO20031860L (no

NO20031860D0 (no

Inventor

Glynn Thomas Faircloth

Graham Keith Ruffles

Bastian Nuyen

Steve Weitman

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-31

Filing date

2003-04-25

Publication date

2011-10-03

2003-04-25 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2003-04-25 Publication of NO20031860D0 publication Critical patent/NO20031860D0/no

2003-06-30 Publication of NO20031860L publication Critical patent/NO20031860L/no

2011-10-03 Publication of NO331082B1 publication Critical patent/NO331082B1/no

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 title abstract 2
108010091711 kahalalide F Proteins 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Liquid Crystal Substances (AREA)
Carbon And Carbon Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compositions Of Macromolecular Compounds (AREA)

NO20031860A 2000-10-31 2003-04-25 Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft NO331082B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US24447100P	2000-10-31	2000-10-31
US24622900P	2000-11-06	2000-11-06
US34844901P	2001-10-19	2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en)	2000-10-31	2001-10-31	Kahalalide f formulation

Publications (3)

Publication Number	Publication Date
NO20031860D0 NO20031860D0 (no)	2003-04-25
NO20031860L NO20031860L (no)	2003-06-30
NO331082B1 true NO331082B1 (no)	2011-10-03

Family

ID=27399760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031860A NO331082B1 (no)	2000-10-31	2003-04-25	Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft

Country Status (22)

Country	Link
US (1)	US7473681B2 (cs)
EP (1)	EP1330258B1 (cs)
JP (2)	JP2004512370A (cs)
KR (1)	KR100834138B1 (cs)
CN (1)	CN1568192A (cs)
AT (1)	ATE314084T1 (cs)
AU (2)	AU1074902A (cs)
BR (1)	BR0114912A (cs)
CA (1)	CA2425627A1 (cs)
CY (1)	CY1105009T1 (cs)
CZ (1)	CZ20031211A3 (cs)
DE (1)	DE60116359T2 (cs)
DK (1)	DK1330258T3 (cs)
ES (1)	ES2256305T3 (cs)
HK (1)	HK1054192B (cs)
HU (1)	HUP0600031A3 (cs)
IL (2)	IL155297A0 (cs)
MX (1)	MXPA03003704A (cs)
NO (1)	NO331082B1 (cs)
NZ (1)	NZ525243A (cs)
SK (1)	SK286421B6 (cs)
WO (1)	WO2002036145A2 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0002952D0 (en)	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
US20050054555A1 (en) *	2001-10-19	2005-03-10	Jose Jimeno	Kahalalide compounds for use in cancer therapy
EP1435990A1 (en) *	2001-10-19	2004-07-14	Pharma Mar, S.A.	Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
KR101149095B1 (ko) *	2002-10-18	2012-05-30	파르마 마르 에스.에이.유.	4-메틸헥사노 카할라리드 ｆ 화합물
EP1572726B1 (en) *	2002-10-18	2010-12-08	Pharma Mar, S.A.U.	4-methylhexanoic kahalalide f compound
US7507708B2 (en) *	2003-02-26	2009-03-24	Pharma Mar, S.A.U.	Antitumoral compounds
DE10329847A1 (de) *	2003-07-02	2005-01-20	Toximed Gmbh	Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) *	2003-09-09	2003-10-08	Pharma Mar Sau	New antitumoral compounds
GB0408958D0 (en) *	2004-04-22	2004-05-26	Pharma Mar Sa	Convergent synthesis for kahalalide compounds
EP1827500B1 (en) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) *	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
WO2009052379A2 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Improved antitumoral treatments
EP2252315A1 (en) *	2008-01-30	2010-11-24	Pharma Mar, S.A.	Improved antitumoral treatments
EP2262522A1 (en) *	2008-03-07	2010-12-22	Pharma Mar, S.A.	Improved antitumoral treatments
WO2009135939A2 (en) *	2008-05-09	2009-11-12	Pharma Mar, S.A.	Depsipeptide for use in cancer therapy
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5037644A (en) *	1986-10-27	1991-08-06	Cetus Corporation	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja)	1988-03-09	1998-09-17	大塚製薬株式会社	インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) *	1988-08-17	1988-09-21	Wellcome Found	Novel combination
IE64738B1 (en)	1990-03-20	1995-09-06	Akzo Nv	Stabilized gonadotropin containing preparations
JP2971680B2 (ja)	1991-10-02	1999-11-08	山之内製薬株式会社	組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja)	1991-10-04	1993-04-20	Yamanouchi Pharmaceut Co Ltd	改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en)	1991-12-10	1996-08-27	University Of Southern California	Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) *	1991-12-20	1998-12-15	Novo Nordisk A/S	Pharmaceutical formulation
GB9302046D0 (en) *	1993-02-03	1993-03-24	Pharma Mar Sa	Antiumoral compound-v
US6274551B1 (en) *	1994-02-03	2001-08-14	Pharmamar, S.A.	Cytotoxic and antiviral compound
JP3927248B2 (ja) *	1995-07-11	2007-06-06	第一製薬株式会社	Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
JPH1014581A (ja)	1996-07-08	1998-01-20	Morinaga Milk Ind Co Ltd	ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
JP4025394B2 (ja) *	1996-09-06	2007-12-19	財団法人化学及血清療法研究所	組織プラスミノーゲン活性化因子医薬組成物
DK0827751T3 (da)	1996-09-06	2003-03-31	Chemo Sero Therapeut Res Inst	Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid
GB9803448D0 (en) *	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
GB9807639D0 (en)	1998-04-14	1998-06-10	Kennedy Rheumatology Inst	Anti-inflammatory agents
WO2000016794A1 (en)	1998-09-23	2000-03-30	Marcus Keep	Neuroimmunophilins for selective neuronal radioprotection
GB0002952D0 (en)	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
US20050054555A1 (en) *	2001-10-19	2005-03-10	Jose Jimeno	Kahalalide compounds for use in cancer therapy

2001
- 2001-10-31 NZ NZ525243A patent/NZ525243A/en unknown
- 2001-10-31 JP JP2002538956A patent/JP2004512370A/ja active Pending
- 2001-10-31 US US10/399,571 patent/US7473681B2/en not_active Expired - Fee Related
- 2001-10-31 HK HK03106441.9A patent/HK1054192B/en not_active IP Right Cessation
- 2001-10-31 CZ CZ20031211A patent/CZ20031211A3/cs unknown
- 2001-10-31 KR KR1020037005347A patent/KR100834138B1/ko not_active Expired - Fee Related
- 2001-10-31 AU AU1074902A patent/AU1074902A/xx active Pending
- 2001-10-31 CA CA002425627A patent/CA2425627A1/en not_active Abandoned
- 2001-10-31 BR BR0114912-1A patent/BR0114912A/pt active Search and Examination
- 2001-10-31 IL IL15529701A patent/IL155297A0/xx unknown
- 2001-10-31 ES ES01978654T patent/ES2256305T3/es not_active Expired - Lifetime
- 2001-10-31 AU AU2002210749A patent/AU2002210749B2/en not_active Ceased
- 2001-10-31 SK SK502-2003A patent/SK286421B6/sk not_active IP Right Cessation
- 2001-10-31 WO PCT/GB2001/004821 patent/WO2002036145A2/en not_active Ceased
- 2001-10-31 EP EP01978654A patent/EP1330258B1/en not_active Expired - Lifetime
- 2001-10-31 DK DK01978654T patent/DK1330258T3/da active
- 2001-10-31 MX MXPA03003704A patent/MXPA03003704A/es active IP Right Grant
- 2001-10-31 DE DE60116359T patent/DE60116359T2/de not_active Expired - Lifetime
- 2001-10-31 CN CNA018182712A patent/CN1568192A/zh active Pending
- 2001-10-31 HU HU0600031A patent/HUP0600031A3/hu unknown
- 2001-10-31 AT AT01978654T patent/ATE314084T1/de active
2003
- 2003-04-08 IL IL155297A patent/IL155297A/en not_active IP Right Cessation
- 2003-04-25 NO NO20031860A patent/NO331082B1/no not_active IP Right Cessation
2006
- 2006-03-24 CY CY20061100415T patent/CY1105009T1/el unknown
2009
- 2009-10-23 JP JP2009244772A patent/JP2010047601A/ja active Pending

Also Published As

Publication number	Publication date
HK1054192B (en)	2006-09-08
KR20030044005A (ko)	2003-06-02
AU1074902A (en)	2002-05-15
SK286421B6 (sk)	2008-09-05
KR100834138B1 (ko)	2008-06-02
DE60116359T2 (de)	2006-09-28
AU2002210749B2 (en)	2006-12-21
WO2002036145A2 (en)	2002-05-10
NZ525243A (en)	2005-01-28
EP1330258A2 (en)	2003-07-30
SK5022003A3 (en)	2003-12-02
ATE314084T1 (de)	2006-01-15
EP1330258B1 (en)	2005-12-28
BR0114912A (pt)	2003-10-14
US7473681B2 (en)	2009-01-06
JP2010047601A (ja)	2010-03-04
CN1568192A (zh)	2005-01-19
WO2002036145A8 (en)	2003-10-23
CZ20031211A3 (cs)	2003-09-17
HK1054192A1 (en)	2003-11-21
HUP0600031A2 (en)	2006-05-29
WO2002036145A3 (en)	2002-10-17
NO20031860L (no)	2003-06-30
PL360848A1 (en)	2004-09-20
ES2256305T3 (es)	2006-07-16
CA2425627A1 (en)	2002-05-10
CY1105009T1 (el)	2010-03-03
IL155297A (en)	2010-05-31
NO20031860D0 (no)	2003-04-25
HUP0600031A3 (en)	2012-02-28
DE60116359D1 (de)	2006-02-02
DK1330258T3 (da)	2006-05-22
MXPA03003704A (es)	2004-05-04
US20040067895A1 (en)	2004-04-08
IL155297A0 (en)	2003-11-23
JP2004512370A (ja)	2004-04-22

Legal Events

Date	Code	Title	Description
2012-06-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO331082B1 (no)	2011-10-03	Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
SE0102315D0 (sv)	2001-06-28	Compounds
CY1110914T1 (el)	2014-02-12	Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
SE0100901D0 (sv)	2001-03-15	New composition
CY1108532T1 (el)	2014-04-09	Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
UY27186A1 (es)	2002-09-30	Formulación farmacéutica
BG66093B1 (bg)	2011-04-29	Състави с контролирано освобождаване, съдържащи нимесулид
HUP0301349A2 (hu)	2003-08-28	IL-11-tartalmú készítmények
DK0994710T3 (da)	2003-01-20	Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin
SE0300831D0 (sv)	2003-03-26	New formulations and use therof
ATE260650T1 (de)	2004-03-15	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
EA200601524A1 (ru)	2007-02-27	Альфа-излучающие частицы гидроксиапатита
ATE478662T1 (de)	2010-09-15	Arzneilösungen enthaltend modafinilverbindungen
DE60112756D1 (de)	2005-09-22	Racecadotril enthaltende trockene pulverformulierung
ITMI20022777A1 (it)	2004-06-28	Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
TW200507838A (en)	2005-03-01	Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
ATE401084T1 (de)	2008-08-15	Torasemid enthaltende lagerstabile pharmazeutische zubereitungen
SE0200657D0 (sv)	2002-03-04	Novel Formulation
ITMI20031714A1 (it)	2005-03-06	Formazioni ad azione antitumorale.
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0001916D0 (sv)	2000-05-23	Novel formulation
HRP20080597T3 (en)	2008-12-31	Cancer combination therapy comprising azd2171 and zd1839
PT1406859E (pt)	2008-01-24	Derivados substituídos de 4-aminociclo-hexanol
DK1273301T3 (da)	2007-01-08	Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration